drugset
Drugs / HLX301
last change Dec 2024 re-read 3 minutes ago

HLX301

targets TIGIT

Developed for
lymphoma · metastatic neoplasm · non-small cell lung carcinoma
Investigated by
Shanghai Henlius Biotech

Trials 2

today NCT05390528 · Ph 1/2 NCT05102214 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05390528 Jun 2022 → Sep 2023 lymphoma, metastatic neoplasm Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1/2 NCT05102214 May 2022 → Sep 2023 non-small cell lung carcinoma Shanghai Henlius Biotech Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2022-03-18 Shanghai Henlius Biotech Regulatory Henlius’ Potential First-in-Class Anti-PD-L1×TIGIT Bispecific Antibody HLX301 IND Approved by NMPA henlius.com ↗
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a Phase 1 clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody (BsAb), in Patients with advanced tumours has been approved by the National Medical Products Administration (NMPA).
2021-11-24 Shanghai Henlius Biotech Regulatory Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia henlius.com ↗
Clinical Trial Notification (“CTN”) has been acknowledged by the Therapeutic Goods Administration (“TGA”), Australia.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HLX301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05390528 ↗
1

NCT05102214 ↗
Route Intravenous “administered as a single intravenous (IV) infusion” NCT05102214 ↗
Target TIGIT “Anti-PDL1 and Anti-TIGIT” NCT05102214 ↗